HKG:1276

3 stories mentioning HKG:1276Updated 34d ago

Every FINWIRES story that references HKG:1276, newest first.

Hong Kong Stocks End Lower as U.S.-Iran Talks Remain Stalled; Hengrui Pharma Jumps

Hong Kong stocks ended slightly lower on Tuesday as fading expectations for progress in U.S.-Iran negotiations and caution ahead of U.S. inflation data weighed on sentiment.The Hang Seng Index shed 0.2%, or 58.93 points, to close at 26,347.91, while the Hang Seng China Enterprises Index barely moved in negative territory to finish at 8,882.37.U.S. President Donald Trump said on Monday that a ceasefire with Iran was "on life support" after Tehran's response to a U.S. proposal highlighted divisions between the two sides.Tehran has called for compensation for war-related damage, an end to the U.S. naval blockade, assurances against further attacks, and the resumption of Iranian oil exports.Markets are also closely watching Trump's visit to China, which begins on Wednesday.In corporate news, Hengrui Pharmaceuticals (HKG:1276, SHA:600276) advanced nearly 5% in Hong Kong after signing a drug development deal with Bristol Myers Squibb worth up to $15.2 billion.

Hang SengHKG:1276SHA:600276

Asia35d ago

Jiangsu Hengrui Pharma Signs $15 Billion Drug Development Deal with Bristol Myers Squibb

Jiangsu Hengrui Pharmaceuticals (HKG:1276, SHA:600276) entered into global collaboration and license agreements with Bristol Myers Squibb to develop 13 early-stage programs across oncology, hematology, and immunology, according to a Tuesday Hong Kong bourse filing.The agreements include four oncology and hematology programs from Hengrui, four immunology programs from Bristol Myers Squibb, and five jointly discovered and developed programs.The U.S.-headquartered biopharma company will pay Hengrui up to $950 million, including a $600 million upfront payment, a $175 million first anniversary payment, and a contingent $175 million payment in 2028.The potential total value of the agreements could reach about $15.2 billion, including milestone payments tied to development, regulatory, and commercial targets.Under the deal, Bristol Myers will obtain exclusive worldwide rights to Hengrui-originated programs outside mainland China, Hong Kong, and Macau, while Hengrui will secure exclusive rights to Bristol Myers Squibb-originated programs within those markets.The companies expect the agreements to close in the third quarter, subject to antitrust review and other customary closing conditions.

HKG:1276SHA:600276

Asia54d ago

Hengrui Pharma's Q1 Profit Climbs 22%

Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) recorded a 22% rise in attributable profit for the first quarter of 2026 to 2.28 billion yuan from 1.87 billion yuan a year prior, according to a Wednesday Hong Kong bourse filing.Earnings per share jumped to 0.34 yuan from 0.30 yuan in the corresponding period of the previous fiscal year.Operating revenue climbed 13% to 8.14 billion yuan from 7.21 billion yuan in the year-ago period.

HKG:1276SHA:600276

Track with the FINWIRES app suite

FolioX

Track HKG:1276 in your portfolio

WheelAI

Analyze HKG:1276 options with the wheel strategy

StockInsider

See market sentiment on HKG:1276